HUMA Company Profile and Key Details

Q: Who are the executives of HUMA?

Dr. Yang Cao M.D., Ph.D.Chief Regulatory OfficerMr. Harold AltersonSenior Vice President of QualityDr. Shamik J. Parikh M.D.Chief Medical OfficerMs. Sabrina OsborneExecutive Vice President of Bus. Strategy & PeopleDr. Heather Ledbetter Prichard Ph.D.Chief Operating OfficerMr. Dale A. SanderChief Financial Officer, Chief Corporation Devel. Officer & TreasurerMr. William John ScheesseleChief Commercial OfficerDr. Juliana L. Blum Ph.D.Co-Founder & Executive AdvisorDr. Laura E. Niklason M.D., Ph.D.Founder, Pres, Chief Executive Officer & Director

NASDAQ : HUMA

Humacyte

$1.31

0.1095+9.13%

Open: 10:47 AM

78.77

A-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Humacyte, Inc. (HUMA) stock surged +9.13%, trading at $1.31 on NASDAQ, up from the previous close of $1.20. The stock opened at $1.22, fluctuating between $1.22 and $1.31 in the recent session.

Stock Snapshot

1.2

Prev. Close

187.02M

Market Cap

1.22

Day Low

-4.85

P/E Ratio

-0.27

EPS (TTM)

-0.73

Cash Flow per Share

1.22

Open

142.82M

Number of Shares

1.31

Day High

79%

Free Float in %

0.13

Book Value

2.71M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 09, 2026	1.12	1.23	1.10	1.20	6.59M
Mar 06, 2026	1.09	1.15	1.08	1.11	3.35M
Mar 03, 2026	1.10	1.12	1.06	1.07	2.58M
Mar 02, 2026	1.09	1.13	1.07	1.12	2.21M
Feb 27, 2026	1.20	1.21	1.10	1.12	4.23M
Feb 26, 2026	1.17	1.26	1.16	1.23	6.05M
Feb 25, 2026	1.11	1.21	1.11	1.16	4.73M
Feb 24, 2026	1.13	1.14	1.04	1.12	5.11M
Feb 23, 2026	1.12	1.17	1.09	1.14	3.5M
Feb 20, 2026	1.12	1.15	1.10	1.13	3.07M
Feb 19, 2026	1.09	1.16	1.07	1.15	4.05M
Feb 18, 2026	1.13	1.14	1.06	1.08	4.51M
Feb 17, 2026	1.03	1.16	1.03	1.14	7.16M
Feb 13, 2026	1.01	1.04	0.98	1.01	3.47M
Feb 12, 2026	1.01	1.04	0.98	1.01	6.71M
Feb 11, 2026	1.07	1.08	0.96	1.01	8.92M
Feb 10, 2026	1.25	1.29	1.04	1.05	13.09M
Feb 09, 2026	1.02	1.29	1.00	1.22	26.52M
Feb 06, 2026	0.93	0.96	0.90	0.94	2.43M
Feb 05, 2026	0.96	0.96	0.88	0.89	4.03M

Contact Details

Durham, NC 27713

United States

https://www.humacyte.com 919 313 9633

About Company

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Stock Peers

REGN

21.74+2.86%

Regeneron Pharmaceuticals, Inc.$781.60 ARGX

22.6+3.15%

argenx SE$740.40 UTHR

51.01+10.67%

United Therapeutics Corporation$529.17 VRTX

4.18+0.92%

Vertex Pharmaceuticals Incorporated$460.87 MDGL

0.37+0.09%

Madrigal Pharmaceuticals, Inc.$433.20 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

2.93+0.91%

Alnylam Pharmaceuticals, Inc.$323.59 PRAX

-1.7-0.55%

Praxis Precision Medicines, Inc.$309.01 KRYS

4.96+1.96%

Krystal Biotech, Inc.$258.65 ASND

-0.73-0.30%

Ascendis Pharma A/S$239.92

Company Overview

Humacyte, Inc. (NASDAQ:HUMA) closed at $1.31 USD, gaining $0.11 (9.13%) from the previous close of $1.20. The stock is currently mid-range between its 52-week high and low $0.88 and $3.36. With a market capitalization of about $187.02 million, Humacyte, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.93). Key stats such as the average daily volume over the past year has been around 5.33 million shares, volume is running light vs its 52-week average. Headquartered in Durham, NC, Humacyte, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Laura E. Niklason, the company employs approximately 218 people and listed since December 01, 2020. Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 15.6%, SMA50 14.58%, SMA200 -26.88%). The stock’s 14-day RSI is 59.82 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.78% below its high and over 39.77% above its low. Average 10-day trading volume of 3.68 million shares is below the 3-month average of 5.27 million, indicating normal recent market interest.

Valuation Metrics

Humacyte, Inc. trades at a P/E ratio of -5.1, slightly below the S&P 500 average, with a price-to-sales ratio of 19.32 and a price-to-book ratio of -39.65 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.6, also above market averages.

Dividend & Fair Value

Humacyte, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.24. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Humacyte, Inc. generated EPS of -$0.24 over the past year. Five-year average earnings growth is 42.43%. Wall Street analysts project EPS growth of 51.26% annually over the next five years. The latest quarter delivered EPS of -$0.11. The next quarter is forecast at -$0.13. Next year's EPS is expected at $10.55. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 28 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $3.00. The high target offers 1983.33% upside. The low target suggests 150.0% downside. The mean target is $18.72. This offers 1460.0% upside. Humacyte, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -35.29%. The prior quarter beat by 60.0%. Over the last six quarters, Apple has recorded several small beats. These include 17.39% in August 13, 2024.

Shareholding & Insider Activity

Humacyte, Inc. has 158.37 million shares outstanding. The public float is 125.19 million shares, elevated short interest at 24.82% of float. This equals 34.25 million shares. The short ratio is 6.17 days. Institutional investors hold 45.32% of the float. Insiders own 19.74%. Ayabudge LLC holds 8.19 million shares, Sebelius Kathleen has 91.21 thousand shares and Binder Gordon M has 50.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Humacyte has not generated any revenue. Returns are negative, with ROA at -86.39% and ROE at -817.78%.
On valuation metrics, Humacyte trades at a P/E of -5.10, P/S of 19.32 and P/B of -39.65. The current ratio is 1.62 and quick ratio is 0.90. Operationally, the company’s inventory turnover is 0.43 and cash conversion cycle is 451.95 days. Debt-to-equity is -6.28, supported by a cash flow-to-debt ratio of -3.54.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Humacyte posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $7.72M (margin 0.00%). Operating income was - $100.05M (margin 0.0%). Net income was- $110.78M (EPS - $1.07).
The company ended the quarter with $80.59M in cash and short-term investments, a total debt of $58.11M, and net debt of - $22.49M. Total assets were $128.22M, with equity of $13.55M. Financials further reflected weakness, with operating cash flow of - $73.31M, free cash flow of - $75.59M, and capital expenditures of - $2.28M.

Price Forecast & Outlook

Our AI price prediction model suggests that Humacyte, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.17%, with price expected at $1.25 by March 23, 2026, within a range of $1.17 to $1.32 3-Month Outlook: Projected fall of -31.67%, reaching $0.82 by June 05, 2026, with a range of $0.72 to $0.94. 1-Year Outlook: Projected loss of -13.33%, with price at $1.04 by March 09, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Humacyte, Inc. (NASDAQ:HUMA) shares are flat 6.19% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Humacyte, Inc. trading at a premium to the broader market with a P/E of -5.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.07, suggesting 1322.5% upside. Our AI forecast model points to short-term strength (4.17% over two weeks), a medium-term fall (-31.67% over three months), and a longer-term loss (-13.33% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Humacyte, Inc. (HUMA) stock price?

Humacyte, Inc. (NASDAQ: HUMA) stock price is $1.31 in the last trading session. During the trading session, HUMA stock reached the peak price of $1.31 while $1.22 was the lowest point it dropped to. The percentage change in HUMA stock occurred in the recent session was 9.13% while the dollar amount for the price change in HUMA stock was $0.11.

HUMA's industry and sector of operation?

The NASDAQ listed HUMA is part of Biotechnology industry that operates in the broader Healthcare sector. Humacyte, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HUMA?

Dr. Yang Cao M.D., Ph.D.
Chief Regulatory Officer
Mr. Harold Alterson
Senior Vice President of Quality
Dr. Shamik J. Parikh M.D.
Chief Medical Officer
Ms. Sabrina Osborne
Executive Vice President of Bus. Strategy & People
Dr. Heather Ledbetter Prichard Ph.D.
Chief Operating Officer
Mr. Dale A. Sander
Chief Financial Officer, Chief Corporation Devel. Officer & Treasurer
Mr. William John Scheessele
Chief Commercial Officer
Dr. Juliana L. Blum Ph.D.
Co-Founder & Executive Advisor
Dr. Laura E. Niklason M.D., Ph.D.
Founder, Pres, Chief Executive Officer & Director

How HUMA did perform over past 52-week?

HUMA's closing price is 36.36% higher than its 52-week low of $0.88 where as its distance from 52-week high of $3.36 is -64.29%.

How many employees does HUMA have?

Number of HUMA employees currently stands at 218.

Link for HUMA official website?

Official Website of HUMA is: https://www.humacyte.com

How do I contact HUMA?

HUMA could be contacted at phone 919 313 9633 and can also be accessed through its website. HUMA operates from 2525 East North Carolina Highway 54, Durham, NC 27713, United States.

How many shares of HUMA are traded daily?

HUMA stock volume for the day was 2.71M shares. The average number of HUMA shares traded daily for last 3 months was 5.33M.

What is the market cap of HUMA currently?

The market value of HUMA currently stands at $187.02M with its latest stock price at $1.31 and 142.82M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	218
Beta	1.93
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

HUMA Company Profile and Key Details

Humacyte

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Valuation Metrics